title: PET imaging for tyrosine kinase inhibitor (TKI) biodistribution in mice.
abstract: Receptor tyrosine kinases play a critical role in cell growth, survival, and proliferation, and are considered potential molecular targets for the treatment of cancer. Although several tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, have demonstrated clinical efficacy via the inhibition of the epidermal growth factor receptor (EGFR), most TKIs are only effective in a small proportion of patients. Positron emission tomography (PET) imaging is a methodology of molecular imaging based on nuclear imaging. PET imaging in combination with radiolabeled TKIs improves accuracy of quantitative imaging strategies and the probability of successful drug development, and may facilitate the stratification of patients. Here, we describe a protocol for PET imaging using radiolabeled TKI in preclinical trials.
authors.affiliation: Bioimaging Research Laboratories, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan, hiroshi.fushiki@astellas.com.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Fushiki
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Murakami
authors.forename: Sosuke
authors.initials: S
authors.lastname: Miyoshi
authors.forename: Shintaro
authors.initials: S
authors.lastname: Nishimura
mesh_terms: D000818:Animals; D007553:Isotope Labeling; D008163:Luminescent Measurements / Q000379:methods; D051379:Mice; D057054:Molecular Imaging / Q000379:methods; D009374:Neoplasms, Experimental / Q000188:drug therapy; D049268:Positron-Emission Tomography / Q000379:methods*; D047428:Protein Kinase Inhibitors / Q000493:pharmacokinetics*; D014018:Tissue Distribution
chemical_list: D047428:Protein Kinase Inhibitors